http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006010047-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5780788f947b5b0f13be10a7081b7c64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ce6565da9b61bff883cd0755db0f3a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6493a5532dcbaf25904407d2c5d3ae1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d4c1b3b13146b19dd6598fe2f5d18487
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9a9ca83900c4bd9e1fe6d898d09e0d12
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4725
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
filingDate 2005-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6086db7205e0b1c60980ff9472cab2df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72ae7bb42259f242ee3c607bbd2fe829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a382cbceab192b6903ed41045d5efce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e0a95335a0eac5e6458352da24e078c
publicationDate 2006-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2006010047-A3
titleOfInvention Methods and compositions for the detection of ovarian cancer
abstract Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind hemoglobin, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8114615-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8597899-B2
priorityDate 2004-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-02071928-A2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491185
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23925

Total number of triples: 31.